Bayhep B Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high global hepatitis b prevalence, liver transplant complications, reliance on plasma derived immunoglobulins, hospital based prophylaxis protocols, public health vaccination programs.

The growth in the forecast period can be attributed to growth in liver transplant procedures, increasing hepatitis screening rates, expansion of antiviral combination therapies, improved healthcare access, rising government hepatitis elimination targets. Major trends in the forecast period include rising use of hepatitis b immune globulin, expansion of post exposure prophylaxis programs, growing liver transplant support therapies, increased focus on viral hepatitis prevention, strengthening of hospital based immunotherapy.

The increasing prevalence of hepatitis B is expected to drive the growth of the bayhep B market in the coming years. Hepatitis B is a viral infection that causes liver inflammation, primarily transmitted through contact with infected blood and body fluids, and can lead to both acute and chronic liver disease. The rise in hepatitis B cases is attributed to factors such as insufficient vaccination coverage, higher transmission rates among high-risk populations, and disruptions in healthcare services during the COVID-19 pandemic, which hindered testing and prevention efforts. Bayhep B, a monoclonal antibody, is used to treat chronic hepatitis B by binding to the hepatitis B surface antigen (HBsAg), reducing viral replication. It helps control infection, improve liver function, and lower the risk of complications. For instance, in April 2025, the Centers for Disease Control and Prevention (CDC), a U.S.-based federal agency, reported 17,650 new chronic hepatitis B cases across 44 states and the District of Columbia in 2023, corresponding to a prevalence rate of 6.1 cases per 100,000 people. Therefore, the growing prevalence of hepatitis B is supporting the expansion of the bayhep B market.

The rising healthcare expenditure is expected to support the growth of the bayhep B market. Healthcare expenditure refers to overall spending on health care goods and services, including personal and collective care, financed through public and private mechanisms. The increase in healthcare spending is driven by the rising prevalence of chronic diseases, which require long-term and often costly treatment. Higher healthcare expenditure facilitates wider adoption of Bayhep B by improving access to advanced hepatitis B immunoglobulin therapies across healthcare settings. It also supports higher treatment quality through investments in specialized biologics, enhancing patient protection and clinical outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% increase in total healthcare expenditure in 2023, compared with 0.9% growth in 2022. Consequently, rising healthcare expenditure is driving the bayhep B market.

The increasing aging population is expected to boost the growth of the bayhep B market. The global rise in the aging population is driven by longer life expectancy and declining birth rates. Bayhep B is particularly important for older individuals for post-exposure prophylaxis against hepatitis B, especially for those with weakened immunity. For instance, in July 2024, the Office of National Statistics, a UK-based producer of official statistics, reported that in 2022, the UK had approximately 12.7 million people aged 65 and over, representing 19% of the total population, with projections suggesting this could rise to 22.1 million (27% of the population) by 2072. Therefore, the increasing aging population is supporting the growth of the bayhep B market.

Major companies operating in the bayhep b market are Bayer Corporation.

North America was the largest region in the bayhep B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bayhep b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bayhep b market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the bayhep b market by increasing costs associated with plasma collection, antibody purification, and compliance driven quality controls. These impacts have influenced pricing across hospital pharmacies and transplant centers, particularly in regions dependent on imported biologics. Asia pacific and middle east markets are more sensitive due to limited domestic production. At the same time, tariffs have supported local plasma fractionation, encouraged regional supply resilience, and strengthened long term hepatitis b prevention efforts.

The bayhep b market research report is one of a series of new reports that provides bayhep b market statistics, including bayhep b industry global market size, regional shares, competitors with a bayhep b market share, detailed bayhep b market segments, market trends and opportunities, and any further data you may need to thrive in the bayhep b industry. This bayhep b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bayhep B is a pharmaceutical product classified as a Hepatitis B immune globulin. It is a plasma-derived biologic containing human immunoglobulin G (IgG) with a high concentration of antibodies specifically targeting the hepatitis B surface antigen (HBsAg). Bayhep B is primarily used for post-exposure prophylaxis to prevent Hepatitis B infection and to prevent Hepatitis B reinfection after liver transplantation in patients with hepatitis B-related liver failure.

The main indications for Bayhep B include chronic and acute Hepatitis B. Chronic Hepatitis B is a long-term liver infection caused by the hepatitis B virus, and Bayhep B helps prevent viral spread, although it is not used to manage active infections. It is distributed through hospital pharmacies, retail pharmacies, clinics, and online portals and is used by end users including adults, geriatric, and pediatric patients.

The bayhep B market consists of sales of Bayhep B (Hepatitis B Immunoglobulin), Bayhep B syringes, and Bayhep B vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.